A
A

AstraZeneca

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Thailand to cease Sinovac vaccine use when stocks end this month

BANGKOK, Oct 18 (Reuters) - Thailand will stop using the COVID-19 vaccine of China's Sinovac SVA.O when its current stock finishes, a senior official said on Monday, having used the shot extensively in combination with Western-developed vaccines. Thailand used over 31.5 million Sinovac doses since February, starting with two doses to frontline work
A
P

India's vaccine effort slows as dose gap trumps output jump

By Krishna N. Das NEW DELHI, Oct 18 (Reuters) - India's vaccination campaign has slowed despite amassing record stockpiles of vaccine, health ministry data showed on Monday, as authorities maintain a wider-than-usual gap between doses in a strategy that has boosted coverage. Domestic production of the AstraZeneca AZN.L vaccine, which accounts for n
A

European stocks rise past two-week highs on earnings optimism

* STOXX 600 on course for weekly gains * Chip stocks boosted by TSMC results * Publicis up on outlook hike (New throughout, updates prices, market activity and comments to close) By Sruthi Shankar and Susan Mathew Oct 14 (Reuters) - European stocks rose on Thursday, hitting the highest in more than two weeks as investors bet a steady economic recov
A
I
L
S
A
G
E
F
U

UK Stocks-Factors to watch on Oct. 11

Oct 11 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening steady on Monday, with futures .FFIc1 marginally down 0.25%. * ASTRAZENECA: AstraZeneca AZN.L said its antibody cocktail, the first protective shot other than vaccines against COVID-19, met its main goals in a late-stage trial, helping reduce severe COVID-19 or death in non-hospitali
A
B
U

UK Stocks-Factors to watch on Oct. 5

Oct. 5 (Reuters) - Britain's futures .FFIc1 were 0.19% higher on Tuesday. * GREGGS: Greggs GRG.L raised its full-year profit outlook after underlying sales in its latest quarter rose 3.5% compared with two years ago despite staffing and supply chain disruption. * ASTRAZENECA: AstraZeneca AZN.L said it had submitted a request with U.S. health regula
A
G
G
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.